Preis: 9,45 $ Wartestücke: 300 spread: 3,05% ..and good luck  

136.059 shares geballert ..max Tickerleuchte: 9,79 ,GrB  

Datum Erster Hoch Tief Schluss     Stücke Volumen
08.04.13 9,73 9,79 9,52  9,60 $ 258.986 2,48 M
GrB  

Platz Frankfurt ..DAX 7.688 Zählerpunkte ,GrB  

31.185 shares durchen Ticker ..und weiter immer weiter immer schneller wie Propeller  

Datum Erster Hoch Tief Schluss     Stücke Volumen
09.04.13 9,56 9,63 9,3925  9,52 $  250.221 2,38 M
GrB  

Kaufpreis pro Anteilsschein: 7,404 € Wartestücke zur Verbriefung: 406 spread: 3,89%
GrB  

Buchsatz:

Datum Erster Hoch Tief Schluss     Stücke Volumen
10.04.13 9,59 9,73 9,50  9,69 $ 232.362 2,05 M

GrB  

Einstand: 9,91 $ Schleife: 1.300 spread: 0,41% buran

Nasdaq  

ask Preis: 9,94 $ Wartezahl: 100 spread: 10,57% ..buran und MfG  

Kauf pro share nur 9,48 $ ..Warte: 500 ..RTK: 9,48 $ = +5,45% über EK

.......HAMMER ..buran  

..also entbrieft und zu häuslichem Geld gemacht

sieht so aus:

Datum Erster Hoch Tief Schluss     Stücke Volumen
17.04.13 9,37 9,37 8,99  9,06 $ * 285.083 2,62 M

..Kurs powert trotzdem dem Zenit entgegen ..Gewinne sind gewollt und erwünscht

buran  

Handelsplatz Geld-Stk. Geld Geld-Brief Brief Brief-Stk. Spread  Zeit
Frankfurt  441 6,809 €    7,074 € 425 3,89% 08:56:11
GrB  

500 auf der Warteschleife bei nem super flachen spread von nur 0,11%  

RT Kauf: 7,126 € Wartestücke bereits 421 spread: 3,89% buran  

RTK: 9,83  $ sind +5,47% über EK ..219.292 Stücke schon durchgedonnert HAMMER  

at the 12th Annual Needham Healthcare Conference14:05 23.04.13


PR Newswire

ALBANY, New York, April 23, 2013

ALBANY, New York, April 23, 2013 /PRNewswire/ -- AMRI (NASDAQ: AMRI) announced today that AMRI Chairman, President and Chief Executive Officer Thomas E. D'Ambra, Ph.D. will present at the 12th Annual Needham Healthcare Conference on Tuesday, April 30, 2013 at 12:50 p.m. ET.

(Logo: http://photos.prnewswire.com/prnh/20120229/NY61160LOGO )

A webcast of the corporate presentation will be available to investors and interested parties by accessing the company's website at www.amriglobal.com. This webcast will be archived for 90 days following the live presentation.

About AMRI

Albany Molecular Research, Inc. (AMRI) is a global contract research and manufacturing organization offering customers fully integrated drug discovery, development and manufacturing services. For over 21 years, AMRI has demonstrated its adaptability as the pharmaceutical and biotechnology industries have undergone tremendous change in response to multiple challenges. This experience, a track record of success and locations in the United States, Europe and Asia now provides our customers with SMARTSOURCING™, a full range of value-added opportunities providing customers informed decision-making, enhanced efficiency and more successful outcomes at all stages of the pipeline. AMRI has also successfully partnered R&D programs and is actively seeking to out-license its remaining programs for further development. For more information about AMRI, please visit our website at www.amriglobal.com or follow us on Twitter (@amriglobal).


Quelle: PR Newswire  

14:05 24.04.13


PR Newswire

ALBANY, New York, April 24, 2013

ALBANY, New York, April 24, 2013 /PRNewswire/ -- AMRI (NASDAQ: AMRI) today announced it will issue first quarter financial results before the opening of the market on Tuesday, May 7, 2013. Following the release of its results, the company will host a conference call and simultaneous webcast at 10 a.m. ET.

(Logo: http://photos.prnewswire.com/prnh/20120229/NY61160LOGO )

The conference call can be accessed by dialing 888-556-4997 (domestic calls) or 719-325-2452 (international calls) at 9:50 a.m. ET and entering passcode 4945957. The webcast will be available live via the Internet and can be accessed on the company's website at www.amriglobal.com. Replays of the webcast can also be accessed for up to 90 days after the call via the investor area of the company's website at www.amriglobal.com/investor_relations/.

About AMRI

Albany Molecular Research, Inc. (AMRI) is a global contract research and manufacturing organization offering customers fully integrated drug discovery, development, and manufacturing services. For over 21 years AMRI has demonstrated its adaptability as the pharmaceutical and biotechnology industries have undergone tremendous change in response to multiple challenges. This experience, a track record of success and locations in the United States, Europe and Asia now provides our customers with SMARTSOURCING™, a full range of value-added opportunities providing customers informed decision-making, enhanced efficiency and more successful outcomes at all stages of the pipeline. AMRI has also successfully partnered R&D programs and is actively seeking to out-license its remaining programs for further development. For more information about AMRI, please visit our website at www.amriglobal.com or follow us on Twitter (@amriglobal).


Quelle: PR Newswire  

superdicke +12,25% über Eröffnung ..max Lecuhte bereits 11,95 ..HAMMER / buran  

Branche sonstige
Herkunft USA
Indizes/Listen NASDAQ
Aktienanzahl 30,8 Mio. (Stand: 11.08.12)
Marktkap. 344,9 Mio. $
GrB  

Kaufpreis: 11,57 $ ..900 auf der Warte ..top Angebot  

http://www.ariva.de/news/...Quarter-2013-Results-and-Raise-4522006GrB  

1.000 in der Warte ..spread: 7,37%
____________________________

..alle Angaben 10:00 MEZ ,GrB  

.......und die heutige Nettigkeit wieder mal ganz in grün:: 11,22 $ +7,37% +0,77 $ RT  

Warteschleife 4.000 ..spread 16,25% ,GrB